EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MSCs derived from ADSC-reprogrammed iPSCs exhibit enhanced therapeutic potential for treating skin fibrosis.

Liquan Wang, Mingfei Lu, Meili Zhang, Lin Kang, Fengzhou Du, Nanze Yu iD, Jiuzuo Huang, Yue Huang iD, Xiao Long iD

Stem Cells Translational Medicine · 2026

DOI: 10.1093/stcltm/szag063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2026. Verfasst von Liquan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Aesthetic Surgery, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Adipose Tissue, Skin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Localized scleroderma (LoS) is a fibrotic skin disorder characterized by excessive collagen deposition, leading to functional and cosmetic impairments. Mesenchymal stromal cells (MSCs) offer therapeutic potential through immunomodulation and tissue repair, but their clinical use is limited by donor variability and replicative senescence. Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) present a promising alternative owing to their scalable production and rejuvenated phenotype.

Methods

We generated adipose-derived iMSCs (AD-iMSCs) from reprogrammed adipose-derived stem cells (ADSCs) and compared their therapeutic efficacy to primary ADSCs in vitro and in vivo. Functional assays including transcriptomic profiling, conditioned medium (CM) effects on fibrosis markers (α-SMA, TGF-β/Smad), and angiogenesis were conducted. A bleomycin-induced murine LoS model was employed to assess AD-iMSC engraftment, collagen deposition, and microvascularization.

Results

AD-iMSCs exhibited rejuvenated-like phenotype, with reduced senescence markers and enhanced proliferative capacity. AD-iMSC-derived conditioned medium (AD-iMSCs-CM) outperformed ADSC-derived conditioned medium (ADSC-CM) in promoting angiogenesis in vitro. In vivo, AD-iMSCs demonstrated superior persistence and therapeutic efficacy, notably decreasing dermal thickness and collagen density while promoting vascularization. Mechanistically, AD-iMSCs more effectively suppressed the TGF-β/Smad2/3 signaling and extracellular matrix (ECM) remodeling pathways compared to ADSCs.

Conclusion

In conclusion, our findings provide a robust preliminary proof-of-concept demonstrating that iPSC-mediated reprogramming yields iMSCs with rejuvenated-like phenotype and a potent anti-fibrotic secretome. These data offer a valuable molecular and functional rationale for the prospective development of iMSC-based platforms to circumvent the expansion limitations and donor variability inherent to primary MSC therapies for fibrotic skin disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsInduced Pluripotent Stem CellsAdipose TissueSkinCellular ReprogrammingMesenchymal Stem Cell TransplantationAnimalsMiceFibrosisHumansCulture Media, ConditionedCell Differentiation

Stichwörter der Autor:innen

TGF-β signalingiPSC-derived MSCsparacrine therapyrejuvenationsclerodermaskin fibrosis

Substanzen

Culture Media, Conditioned

Autor:innen und Institutionen

  • Department of Plastic and Aesthetic Surgery, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100005, China.
  • State Key Laboratory of Common Mechanism Research for Major Diseases, Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medi…

ORCID-Profile: Nanze Yu, Yue Huang, Xiao Long

Förderung

  • National Natural Science Foundation of China
  • National High Level Hospital Clinical Research Funding
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Wang, L., Lu, M., Zhang, M., Kang, L., Du, F., Yu, N., Huang, J., Huang, Y., & Long, X. (2026). MSCs derived from ADSC-reprogrammed iPSCs exhibit enhanced therapeutic potential for treating skin fibrosis. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szag063

Vancouver

Wang L, Lu M, Zhang M, Kang L, Du F, Yu N, et al. MSCs derived from ADSC-reprogrammed iPSCs exhibit enhanced therapeutic potential for treating skin fibrosis. Stem Cells Translational Medicine. 2026. doi:10.1093/stcltm/szag063

BibTeX
@article{Wang2026,
  author = {Wang, Liquan and Lu, Mingfei and Zhang, Meili and Kang, Lin and Du, Fengzhou and Yu, Nanze and Huang, Jiuzuo and Huang, Yue and Long, Xiao},
  title = {MSCs derived from ADSC-reprogrammed iPSCs exhibit enhanced therapeutic potential for treating skin fibrosis},
  journal = {Stem Cells Translational Medicine},
  year = {2026},
  doi = {10.1093/stcltm/szag063}
}
Kostenlos starten →